C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 5.6 USD 0.18% Market Closed
Market Cap: 75m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

Intrinsic Value

CASI's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CASI stock under the Base Case scenario is 12.43 USD. Compared to the current market price of 5.6 USD, CASI Pharmaceuticals Inc is Undervalued by 55%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CASI Intrinsic Value
12.43 USD
Undervaluation 55%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
CASI Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CASI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CASI?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about CASI Pharmaceuticals Inc

Provide an overview of the primary business activities
of CASI Pharmaceuticals Inc.

What unique competitive advantages
does CASI Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does CASI Pharmaceuticals Inc face in the near future?

Summarize the latest earnings call
of CASI Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CASI Pharmaceuticals Inc.

Provide P/S
for CASI Pharmaceuticals Inc.

Provide P/E
for CASI Pharmaceuticals Inc.

Provide P/OCF
for CASI Pharmaceuticals Inc.

Provide P/FCFE
for CASI Pharmaceuticals Inc.

Provide P/B
for CASI Pharmaceuticals Inc.

Provide EV/S
for CASI Pharmaceuticals Inc.

Provide EV/GP
for CASI Pharmaceuticals Inc.

Provide EV/EBITDA
for CASI Pharmaceuticals Inc.

Provide EV/EBIT
for CASI Pharmaceuticals Inc.

Provide EV/OCF
for CASI Pharmaceuticals Inc.

Provide EV/FCFF
for CASI Pharmaceuticals Inc.

Provide EV/IC
for CASI Pharmaceuticals Inc.

Show me price targets
for CASI Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for CASI Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for CASI Pharmaceuticals Inc?

What are the Net Income projections
for CASI Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for CASI Pharmaceuticals Inc?

What are the EPS projections
for CASI Pharmaceuticals Inc?

How accurate were the past EPS estimates
for CASI Pharmaceuticals Inc?

What are the EBIT projections
for CASI Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for CASI Pharmaceuticals Inc?

Compare the revenue forecasts
for CASI Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CASI Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CASI Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of CASI Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of CASI Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing CASI Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of CASI Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for CASI Pharmaceuticals Inc.

Provide ROE
for CASI Pharmaceuticals Inc.

Provide ROA
for CASI Pharmaceuticals Inc.

Provide ROIC
for CASI Pharmaceuticals Inc.

Provide ROCE
for CASI Pharmaceuticals Inc.

Provide Gross Margin
for CASI Pharmaceuticals Inc.

Provide Operating Margin
for CASI Pharmaceuticals Inc.

Provide Net Margin
for CASI Pharmaceuticals Inc.

Provide FCF Margin
for CASI Pharmaceuticals Inc.

Show all solvency ratios
for CASI Pharmaceuticals Inc.

Provide D/E Ratio
for CASI Pharmaceuticals Inc.

Provide D/A Ratio
for CASI Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for CASI Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for CASI Pharmaceuticals Inc.

Provide Quick Ratio
for CASI Pharmaceuticals Inc.

Provide Current Ratio
for CASI Pharmaceuticals Inc.

Provide Cash Ratio
for CASI Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for CASI Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for CASI Pharmaceuticals Inc?

What is the current Free Cash Flow
of CASI Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for CASI Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CASI Pharmaceuticals Inc

Current Assets 59.3m
Cash & Short-Term Investments 18.8m
Receivables 10.1m
Other Current Assets 30.4m
Non-Current Assets 15.9m
Long-Term Investments 1.7m
PP&E 11.6m
Intangibles 1.8m
Other Non-Current Assets 766k
Current Liabilities 16.7m
Accounts Payable 4.4m
Accrued Liabilities 12.3m
Non-Current Liabilities 34.4m
Long-Term Debt 18.9m
Other Non-Current Liabilities 15.5m
Efficiency

Earnings Waterfall
CASI Pharmaceuticals Inc

Revenue
33.9m USD
Cost of Revenue
-13.8m USD
Gross Profit
20.1m USD
Operating Expenses
-45.3m USD
Operating Income
-25.3m USD
Other Expenses
-1.7m USD
Net Income
-27m USD

Free Cash Flow Analysis
CASI Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CASI Profitability Score
Profitability Due Diligence

CASI Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
ROIC is Increasing
25/100
Profitability
Score

CASI Pharmaceuticals Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

CASI Solvency Score
Solvency Due Diligence

CASI Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Positive Net Debt
38/100
Solvency
Score

CASI Pharmaceuticals Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CASI Price Targets Summary
CASI Pharmaceuticals Inc

Wall Street analysts forecast CASI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CASI is 6.12 USD with a low forecast of 6.06 USD and a high forecast of 6.3 USD.

Lowest
Price Target
6.06 USD
8% Upside
Average
Price Target
6.12 USD
9% Upside
Highest
Price Target
6.3 USD
13% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CASI?

Click here to dive deeper.

Dividends

CASI Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CASI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

CASI Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

74.9m USD

Dividend Yield

0%

Description

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company is headquartered in Rockville, Maryland and currently employs 168 full-time employees. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States and throughout the world. The company is also focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which include CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include CNCT19, BI-1206, CB-5339 and CID-103.

Contact

MARYLAND
Rockville
9620 Medical Center Dr Ste 300
+12408642600.0
www.casipharmaceuticals.com

IPO

1996-06-12

Employees

168

Officers

Chairman & CEO
Dr. Wei-Wu He Ph.D.
Executive VP & Chief Medical Officer
Dr. Alexander A. Zukiwski M.D.
Senior Vice President
Dr. Wei Zhang Ph.D.
MD, Senior VP & Chief Financial Officer
Dr. Daniel Lang M.D.
Chief Operating Officer
Ms. Chunhua Wang
General Counsel
Ms. Wei Gao
Show More
Chief Business Development Officer
Dr. James E. Goldschmidt Ph.D.
Global Chief Commercial Officer & GM of CASI China
Mr. Hai Huang
VP & Global Controller
Ms. Kun Qian
Show Less

See Also

Discover More
What is the Intrinsic Value of one CASI stock?

The intrinsic value of one CASI stock under the Base Case scenario is 12.43 USD.

Is CASI stock undervalued or overvalued?

Compared to the current market price of 5.6 USD, CASI Pharmaceuticals Inc is Undervalued by 55%.

Back to Top